Product Description
NV-1020 is a recombinant oncolytic HSV-based virus, in development by MediGene (formerly NeuroVir) for the potential treatment of cancer.
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: MediGene
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Liver Cancer|Colorectal Cancer
Phase 1: Colorectal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CT1030 | P2 |
Completed |
Liver Cancer|Colorectal Cancer |
2008-10-01 |
2020-10-26 |
Primary Endpoints|Treatments |
|
| MSKCC-00022 | P1 |
Completed |
Colorectal Cancer |
2002-11-01 |
2019-03-21 |
Recent News Events
Date |
Type |
Title |
|---|